AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00799058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug placebo
Description: HEC-based universal placebo gel, 2.5g applied once daily
Study NCT00985244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin during 1 year.
Study NCT00985244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Persons in this group will receive 3 times a week placebo of azithromycin during 1 year.
Study NCT03488082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fMRI
Description: saccadic adaptation (target presentations, with or without target jump) during fMRI exam
Study NCT02060812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group I, SSNB & ANB
Description: Suprascapular nerve block (SSNB) and axillary nerve block(ANB) were performed by one anesthesiologist under sono-guidance. 23 gauge spinal needle was used. SSNB was done at first and the entry site was the mid point between an anterolateral angle of acromion and medial end of scapular spine. With the linear probe, the suprascapular notch was identified and the block was performed penetrating the transverse scapular ligament because the scapular nerve and artery were located at the suprascapular notch. Just after the SSNB, ANB was performed and the entry site was the point 1.5 cm medial and 2cm inferior to posterolateral angle of acromion. With the linear probe, posterior circumflex artery was identified and the block was done at just above the artery.
Study NCT02060812 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Group II, SSNB alone
Description: This is same as the Group I, SSNB \& ANB, but ANB was performed with placebo(10mL normal saline).
Study NCT04620408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: Subjects were randomly divided into the group A, B. On D1, D8, two groups of subjects were respectively given SHR4640 tablet.
Study NCT03159247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eyeGuide
Description: The eyeGuide, a web-based tool to facilitate a personalized behavior change program for non-adherent glaucoma patients.
Study NCT01811472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Description: LCQ908 5 mg, 10 mg, 20 mg tablets
Study NCT01811472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets.
Study NCT01461772 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
Study NCT01461772 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
Study NCT01461772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin 130mg/m2BSA on day 1,8,15,22,29,and 36
Study NCT04350411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional diathermy
Description: Abdominal free flap raise performed with conventional diathermy. Settings: cutting 40 Watt, coagulation 40 Watt.
Study NCT04350411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade™
Description: Abdominal free flap raise performed with PEAK PlasmaBlade™ Settings: cutting 7 (35 Watt), coagulation 7 (35 Watt)
Study NCT02371655 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: A low-fibre diet for three days before the examination
Study NCT02371655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faecal Tagging
Description: Oral ingestion of iodinated contrast media (Gastrografin 60 ml) 3h before the examination
Study NCT02371655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faecal Tagging
Description: Oral ingestion of iodinated contrast media (Gastrografin 60 ml) 3h before the examination
Study NCT02371655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bowel cleansing
Description: Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination
Study NCT02371655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bowel cleansing
Description: Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination
Study NCT02371655 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT colonography
Description: CT Examination of the colon aimed to detect polyps and cancer
Study NCT02371655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT colonography
Description: CT Examination of the colon aimed to detect polyps and cancer
Study NCT02898376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin-oriented spa care
Description: standardized procedure : 72 care sessions over 18 days of treatment~+/- Additional care according to the specificity of each spa
Study NCT02898376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: 400 mg bid during at least 6 months
Study NCT02898376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: 400 mg bid during at least 6 months
Study NCT00315016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fosinopril
Description: doubling of fosinopril dose
Study NCT00315016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (double dummy)
Study NCT01461772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 40mg/m2BSA on day 1,8,15,22,29,and 36
Study NCT00924911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322
Description: Four different formulations of 1000mg of GSK1322322
Study NCT02097654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SENATOR software generated pharmacotherapy advice report.
Study NCT04519697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Adult allogeneic bone marrow derived mesenchymal stem cells for the treatment of rectovaginal fistulas in the setting of Crohn's disease.
Study NCT04519697 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT02578186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine Hydrochloride
Description: 30 mL at bedtime
Study NCT02578186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 mL at bedtime
Study NCT03323801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis retinoic acid
Description: Accutane is used for the treatment of severe acne
Study NCT02021955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: guideline treatment recommendations
Description: Primary care clinicians receive guideline concordant treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
Study NCT02302391 — intervention group
Intervention type: OTHER
Intervention: PK analysis
Description: Quantification of Serum Levels and subsequent pharmacokinetic (PK) modelling.
Study NCT04623840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tadalafil 5Mg Tab + continuous and interval exercise
Description: (n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, in addition to 3 sessions, per week, of combined continuous and interval aerobic exercise for eight weeks
Study NCT04623840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5Mg Tab
Description: (n=30) will be sedentary obese men with ED. All participants will receive five milligrams of tadalafil, one time per day, for eight weeks
Study NCT02549131 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Randomizing to Suture or Staple closure of Cesarean section
Description: Randomizing to either surgical subcuticular suture or surgical staples in women of BMI greater than 40 undergoing Cesarean section delivery.
Study NCT03659071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire VSP-A
Description: VSP-A (écu et Santé Perçue de l'Adolescent et de l'enfant): Lived and perceived health of the adolescent and child developed from the exclusive point of view of the child, for which reference values in French population are available. The self-questionnaire used is a questionnaire developed and validated in French for children and adolescents, according to the standards in force, apprehending 9 dimensions (vitality, psychological well-being, relations with friends, leisure, family relations, good physical, relationships with teachers, school work, self-esteem)
Study NCT03659071 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire VSP-A
Description: VSP-A (écu et Santé Perçue de l'Adolescent et de l'enfant): Lived and perceived health of the adolescent and child developed from the exclusive point of view of the child, for which reference values in French population are available. The self-questionnaire used is a questionnaire developed and validated in French for children and adolescents, according to the standards in force, apprehending 9 dimensions (vitality, psychological well-being, relations with friends, leisure, family relations, good physical, relationships with teachers, school work, self-esteem)
Study NCT03908814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole Human Anti-PD-L1 Antibody Injection (LDP)
Description: Dose escalation study evaluating six dose levels (0.1, 0.3, 1, 3 , 10and 20 mg/kg) of LDP.
Study NCT01523509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiographic contrast agent. Sodium Iodide.
Description: Application of Sodium Iodide contrast topically to tooth immediately followed by radiograph.
Study NCT03405818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavaborole 5% Topical Solution
Description: topical solution for application to toenails
Study NCT04317989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: 1. Implementing evidence-based protocols and the use of clinical algorithms (for screening, counseling, referral, and MAT) to engage the entire clinical team in a high standard delivery of care.~2. Promoting a strong use of decision support tools and templates to support the practice workflow.~3. Optimizing the use of the electronic health record (EHR) to pull clinical data on a monthly basis to guide the change process.~4. Developing patient registries (e.g., for those identified to have AUD) to identify needed care~5. Proactive, team-based care with assigned roles and responsibilities to prepare the clinical team to develop needed care and engage patients throughout the entire visit process.~6. Enhancing the understanding of available counseling and referral resources to ensure that practices are confident that they have appropriate evidence-based intervention options.
Study NCT01834352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Walnut Protein Flour
Description: Daily ingestion of gradually increasing amounts of walnut protein flour in order to induce desensitization to walnut and an unrelated tree nut.
Study NCT01834352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oat flour
Description: Oat flour that is administered as a placebo in identical increasing doses as the active walnut flour treatment.
Study NCT02237755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: clomiphene citrate 100mg/day will be added to the standard gonadotropin regiment
Study NCT02237755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
Study NCT03193710 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Propofol will be used for anesthesia maintenance in the total intravenous anesthesia group.
Study NCT03193710 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: Sevoflurane will be used for anesthesia maintenance in the inhalation anesthesia group.
Study NCT03193710 — intervention group
Intervention type: DRUG
Intervention: Remifentanil
Description: Remifentanil will be used for analgesia in both groups.
Study NCT00924911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322
Description: GSK1322322 1000mg
Study NCT01371097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Resistance strength training
Description: Resistance strength training is given as circle training. The resistance is increased with regularly intervals.
Study NCT02691845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HE (health education)
Study NCT02691845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBEX (cognitive-behavioral sessions focused on increasing and maintaining exercise)
Study NCT04160793 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Genital Nerve Stimulation
Description: Implantation the vaginal way a stimulation's electrode to the dorsal nerve of the clintoris in local anesthesia
Study NCT03302728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 15mg
Description: At commencement of study : Lenalidomide will commence at 15 mg daily for days 1-14 of each cycle. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may vary from 5 mg -25 mg daily depending on dose escalation results and recommendation of safety committee
Study NCT03302728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin 1.8 mg/Kg
Description: At commencement of study : Brentuximab vedotin 1.8mg/kg IV on day 1, repeated every 21 days. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may be either 1.2 mg/Kg q21 days or 1.8 mg/kg q21 days depending on dose escalation results and recommendation of safety committee
Study NCT00819416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% albumin
Description: 5% albumin for the first 7 days of care in the ICU
Study NCT00819416 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline
Description: Normal Saline for the first 7 days of care in the ICU
Study NCT02898376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocopherol acetate
Description: 500 mg bid during at least 6 months
Study NCT02898376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocopherol acetate
Description: 500 mg bid during at least 6 months
Study NCT01699815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Study NCT00324519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley bulb
Study NCT00324519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Study NCT02849548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Description: First in class orexin antagonist approved by the FDA for the treatment of insomnia
Study NCT02849548 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pill with inactive ingredients
Study NCT01785979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone induction - chloroquine
Description: At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
Study NCT01785979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
Study NCT00665600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HCl
Description: Levalbuterol 0.63 TID
Study NCT00665600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HCl
Description: Levabuterol 1.25 mg TID
Study NCT00665600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate
Description: Racemic albuterol 2.5 mg TID
Study NCT00665600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo TID
Study NCT03118128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850 mg PO three times a day plus prednisone in one 7-days cycle as pre-treatment and during the 28 days induction remission treatment, consolidation therapy and maintenance
Study NCT00880347 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Blood sampling
Description: Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)
Study NCT04006665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasonography (Baseline)
Description: Lung Ultrasonography will be performed prior to docking Robotic arms in basal three lung zones on both sides.
Study NCT04006665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasonography ( At the end of surgery)
Description: Lung Ultrasonography will be performed after removal of Robotic arms and before extubation in basal three lung zones on both sides to assess degree of atelectasis.
Study NCT01113593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foradil Aerolizer
Description: Dry powder inhaler
Study NCT03031353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprostol is given before elective cesarean section as prophylaxis against post partum hemorrhage
Study NCT03031353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: placebos tablet will be given before elective Cesarean sections
Study NCT01428622 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Respimat
Description: aqueous and ethanolic solution
Study NCT01428622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat
Description: aqueous and ethanolic solution
Study NCT01428622 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: aqueous and ethanolic solution
Study NCT01428622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olodaterol
Description: aqueous solution
Study NCT01428622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: aqueous solution
Study NCT01428622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olodaterol
Description: aqueous solution
Study NCT03633461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-02 (simpinicline) nasal spray
Description: OC-02 (simpinicline) nasal spray, 11.1 mg/ml
Study NCT01428622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olodaterol & BI54903
Description: ethanolic solution
Study NCT01428622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol & BI54903
Description: ethanolic solution
Study NCT01428622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olodaterol & BI54903
Description: ethanolic solution
Study NCT03633461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle) nasal spray
Description: Placebo (vehicle) nasal spray
Study NCT01081002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 10%
Description: 3 min before the endoscopy under propofol sedation 4 puffs of lidocaine 10% will be sprayed on the pharynx as a pharyngeal anesthesia
Study NCT01081002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diluted gentian root solution
Description: As a basis, an infusion of water (45%), ethanol (35%) and gentian root cut will be used. The gentian root infusion is approved as a natural flavor in the food industry.3 min before the endoscopy under propofol sedation 4 puffs of this gentian root infusion will be sprayed on the pharynx as a pharyngeal anesthesia
Study NCT00896974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00896974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies